share_log

UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

GlobeNewswire ·  Jan 31, 2023 16:30

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET.

Rain Oncology Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced that Avanish Vellanki, Chief Executive Officer of Rain, will be participating in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on Thursday, February 9, 2023, at 3:55 p.m. ET, being held in New York, NY.

A live webcast of the fireside chat can be accessed here. A replay of the event will be available on the "Events" section of the Rain website after the conclusion of the event and will be archived on the Rain website at .

About Rain Oncology Inc.
Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of the p53-MDM2 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com  


Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment